ArticleMolecular and clinical oncology2018
Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma.
Article in Molecular and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Prognostic value of the C-reactive protein to albumin ratio in esophageal cancer: A systematic review and meta-analysis.The Kaohsiung journal of medical sciences · 2020Pooled it
- Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis.BMC cancer · 2019Pooled it
- The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma: A meta-analysis.Medicine · 2019Pooled it
- Prognostic role of neutrophil-lymphocyte ratio in esophageal cancer: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Relationship of nutritional or systemic inflammatory markers with efficacy of gemcitabine and cisplatin with or without durvalumab therapy for patients with unresectable or metastatic biliary tract cancer: a retrospective study.Journal of pharmaceutical health care and sciences · 2026Article
- High preoperative Glasgow prognostic score increases a risk of hospital mortality in elderly patients with perihilar cholangiocarcinoma.Journal of hepato-biliary-pancreatic sciences · 2025Article
- The Preoperative C-reactive Protein/Albumin Ratio of Immune-inflammation Index Is an Independent Prognostic Factor of Advanced Colorectal Cancer in Older Patients (≥ 65 years).Journal of the anus, rectum and colon · 2025Article
- C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.Targeted oncology · 2024Article
- Evaluating prognostic significance of preoperative C-reactive protein to albumin ratio in older patients with pathological stage II or III colorectal cancer.Annals of coloproctology · 2024Article
- C-reactive protein-to-albumin ratio and six-month mortality in incident hemodialysis patients.Renal failure · 2023Article
- The use of the ratio of C-reactive protein to albumin for the diagnosis of pediatric septic arthritis.Frontiers in pediatrics · 2023Article
- Use of the C-Reactive Protein (CRP)/Albumin Ratio as a Severity Tool in Acute Pancreatitis: Systematic Review.Cureus · 2022Review
- The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.Journal of thoracic disease · 2020Article
- Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.Medical oncology (Northwood, London, England) · 2019Article
- Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis.Cancer management and research · 2019Article
- The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer: a meta-analysis.Cancer management and research · 2019Article
- The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis.Cancer management and research · 2018Article
- Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal Cancer Treatment.In vivo (Athens, Greece)Review
- Comparative Analysis of Immunoinflammatory and Nutritional Measures in Surgically Resected Esophageal Cancer: A Single-center Retrospective Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the prognostic value of the C-reactive protein-to-albumin ratio (CAR) and compare it with other inflammation-based prognostic scores (Glasgow prognostic score, modified Glasgow prognostic score, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and prognostic index) in patients with esophageal squamous cell cancer (ESCC). A database of 116 patients with primary ESCC who underwent treatment at the Division of Surgical Oncology at Nagasaki University Hospital between January 2007 and August 2014 was retrospectively reviewed and the correlations between CAR and overall survival (OS) were investigated. Kaplan-Meier and Cox regression analyses were used to assess independent prognostic factors. The area under the curve (AUC) was used to compare the prognostic value of different scores. According to the receiver operator characteristics analysis, the recommended cut-off value for CAR was 0.042, with an AUC of 0.678 (sensitivity 31.1%, specificity 66.7%). Thus, patients were dichotomized into low (<0.042) and high (≥0.042) CAR groups. On multivariate analysis, CAR was found to be significantly associated with OS in patients with ESCC [hazard ratio (HR)=2.350; 95% confidence interval (CI): 1.189-4.650; P=0.014], as was tumor-node-metastasis stage (HR=3.059; 95% CI: 1.422-6.582; P=0.004). In addition, CAR had a higher AUC value (0.678) compared with several other systemic inflammation-based prognostic scores (P<0.001). This study suggested that CAR is a novel and promising inflammation-based prognostic score in patients with ESCC. Due to its simplicity, affordability and availability, CAR may be important for improving clinical decision-making and may contribute to more rational study design and analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.